Cargando…
Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
Objective Anticoagulation management in patients with atrial fibrillation (AF) and impaired renal function is challenging. This study aimed to evaluate anticoagulation prescription patterns in relation to renal function and to describe 2-year clinical outcomes among dabigatran users. Methods Globa...
Autores principales: | van der Wall, Sake J., Teutsch, Christine, Dubner, Sergio J., Diener, Hans-Christoph, Halperin, Jonathan L., Ma, Chang Sheng, Rothman, Kenneth J., Paquette, Miney, Zint, Kristina, França, Lionel Riou, Lu, Shihai, Lip, Gregory Y. H., Huisman, Menno V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867412/ https://www.ncbi.nlm.nih.gov/pubmed/33564743 http://dx.doi.org/10.1055/s-0040-1722706 |
Ejemplares similares
-
Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
por: Kozieł, Monika, et al.
Publicado: (2020) -
Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020) -
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020) -
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
por: Mazurek, Michał, et al.
Publicado: (2017) -
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
por: Beier, Lea, et al.
Publicado: (2022)